Computational studies suggest compounds restoring function of p53 cancer mutants can bind SARS-CoV-2 spike protein

References

• Aloni-Grinstein, R., Charni-Natan, M., Solomon, H., & Rotter, V. (2018). Rotter, V. p53 and the viral connection: Back into the future. Cancers, 10(6), 178. doi: 10.3390/cancers10060178
   PubMed Web of Science ®Google Scholar
• Asmana, N. R. (2014). Human interferon alpha-2b: A therapeutic protein for cancer treatment. Scientifica (Cairo), 2014, 970315.
   PubMedGoogle Scholar
• Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A., & Haak, J. R. (1984). Molecular dynamics with coupling to an external bath. The Journal of Chemical Physics, 81(8), 3684–3690. https://doi.org/10.1063/1.448118
   Web of Science ®Google Scholar
• Bitencourt-Ferreira, G., Veit-Acosta, M., & Azevedo, W. F. D. Jr. (2019). Van der Waals potential in protein complexes. Docking screens for drug discovery. Methods in Molecular Biology, 2053, 79–91.
   PubMedGoogle Scholar
• Bussi, G., Donadio, D., & Parrinello, M. (2007). Canonical sampling through velocity rescaling. The Journal of Chemical Physics, 126(1), 014101–014107.
   PubMed Web of Science ®Google Scholar
• Cook, A. M., McDonnell, A. M., Lake, R. A., & Nowak, A. K. (2016). Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. Oncoimmunology, 5(3), e1066062. https://doi.org/10.1080/2162402X.2015.1066062
   PubMed Web of Science ®Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717.
   PubMed Web of Science ®Google Scholar
• Dassault Systèmes BIOVIA. (2017). Discovery Studio Modeling Environment, Release 2017. Dassault Systèmes.
   Google Scholar
• Deganutti, G., Prischi, F., & Reynolds, C. A. (2021). Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein. Journal of Computer-Aided Molecular Design, 35(2), 195–207. https://doi.org/10.1007/s10822-020-00356-4
   PubMed Web of Science ®Google Scholar
• Ebrahimi, K. H. (2020). SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection. FEBS Letters, 594, 1651–1660.
   PubMed Web of Science ®Google Scholar
• Elgohary, S., Elkhodiry, A. A., Amin, N. S., Stein, U., & El Tayebi, H. M. (2021). Thymoquinone: A tie-breaker in SARS-CoV2-infected cancer patients? Cells, 10(2), 302. https://doi.org/10.3390/cells10020302
   PubMed Web of Science ®Google Scholar
• Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. A., Urquiza, J., Ramirez, D., Alonso, C., Campillo, N. E., & Martinez, A. (2020). COVID-19: Drug targets and potential treatments. Journal of Medicinal Chemistry, 63(21), 12359–12386.
   PubMed Web of Science ®Google Scholar
• Grosdidier, A., Zoete, V., & Michielin, O. (2011). SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Research, 39(Web Server issue), W270–W277.
   PubMed Web of Science ®Google Scholar
• Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., Santoro, A., Di Gaetano, M., Puzzolante, C., Carli, F., Bedini, A., Corradi, L., Fantini, R., Castaniere, I., Tabbì, L., … Mussini, C. (2020). Tocilizumab in patients with severe COVID-19: A retrospective cohort study. The Lancet Rheumatology, 2(8), e474–e84. https://doi.org/10.1016/S2665-9913(20)30173-9
   PubMedGoogle Scholar
• Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14(1), 33–38.
   PubMedGoogle Scholar
• Kelley, L. A., Gardner, S. P., & Sutcliffe, M. J. (1996). An automated approach for clustering an ensemble of NMR-derived protein structures into conformationally related subfamilies. Protein Engineering, 9(11), 1063–1065.
   PubMedGoogle Scholar
• Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., Grivas, P., Painter, C. A., Peters, S., Thompson, M. A., Bakouny, Z., Batist, G., Bekaii-Saab, T., Bilen, M. A., Bouganim, N., … Warner, J. L., COVID-19 and Cancer Consortium. (2020). Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study. Lancet (London, England), 395(10241), 1907–1918.
   PubMed Web of Science ®Google Scholar
• Kumar, Y., Singh, H., & Patel, C. N. (2020). In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Journal of Infection and Public Health, 13(9), 1210–1223. https://doi.org/10.1016/j.jiph.2020.06.016
   PubMed Web of Science ®Google Scholar
• Kumari, R., Kumar, R., & Lynn, A., Open Source Drug Discovery Consortium. (2014). Open source drug discovery consortium; Lynn, A. g_mmpbsa - A GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. https://doi.org/10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Kupferschmidt, K., & Cohen, J. (2020). Will novel virus go pandemic or be contained? Science (New York, N.Y.), 367(6478), 610–611. https://doi.org/10.1126/science.367.6478.610
   PubMed Web of Science ®Google Scholar
• La Rosée, F., Bremer, H. C., Gehrke, I., Kehr, A., Hochhaus, A., Birndt, S., Fellhauer, M., Henkes, M., Kumle, B., Russo, S. G., & La Rosée, P. (2020). The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia, 34(7), 1805–1815. https://doi.org/10.1038/s41375-020-0891-0
   PubMed Web of Science ®Google Scholar
• Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., & Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 581(7807), 215–220. https://doi.org/10.1038/s41586-020-2180-5
   PubMed Web of Science ®Google Scholar
• Lauer, Y. M., & Lozoya, J. C. (2016). p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. Proceedings of the National Academy of Sciences, 113(35), E5 192–E5 201. https://doi.org/10.1073/pnas.1603435113
   Web of Science ®Google Scholar
• Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005). Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science (New York, N.Y.), 309(5742), 1864–1868. https://doi.org/10.1126/science.1116480
   PubMed Web of Science ®Google Scholar
• Luecke. (2015). Small molecules for restoring function to p53 cancer mutants. United States Patent Application Publication (Pub. No. US 2015/0307519 A1).
   Google Scholar
• MacKerell, A. D., Jr.Feig, M., & Brooks, I. I. I C. L. (2004). Improved treatment of the protein backbone in empirical force fields. Journal of the American Chemical Society, 126(3), 698–699.
   PubMed Web of Science ®Google Scholar
• Maringe, C., Spicer, J., Morris, M., Purushotham, A., Nolte, E., Sullivan, R., Rachet, B., & Aggarwal, A. (2020). The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: A national, population-based, modelling study. The Lancet. Oncology, 21(8), 1023–1034.
   PubMed Web of Science ®Google Scholar
• Mark, P., & Nilsson, L. (2001). Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. The Journal of Physical Chemistry A, 105(43), 9954–9960. https://doi.org/10.1021/jp003020w
   Web of Science ®Google Scholar
• Massova, I., & Kollman, P. A. (2000). Combined molecular mechanical and continuum solvent approach (MM- PBSA/GBSA) to predict ligand binding. Perspectives in Drug Discovery and Design, 18(1), 113–135. https://doi.org/10.1023/A:1008763014207
   Google Scholar
• Miroshnychenko, K. V., & Shestopalova, A. V. (2021). Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: The results of a molecular simulation study. Journal of Biomolecular Structure and Dynamics, 1–15. https://doi.org/10.1080/07391102.2021.1914168
   Google Scholar
• Nandi, S., Kumar, M., & Saxena, A. K. (2021). Repurposing of drugs and HTS to combat SARS-CoV-2 main protease utilizing structure-based molecular docking. Letters in Drug Design & Discovery. https://doi.org/10.2174/1570180818666211007111105
   Google Scholar
• Nandi, S., Kumar, M., Saxena, M., & Saxena, A. K. (2021). The antiviral and antimalarial drug repurposing in quest of chemotherapeutics to combat COVID-19 utilizing structure-based molecular docking. Combinatorial Chemistry & High Throughput Screening, 24(7), 1055–1068.
   PubMed Web of Science ®Google Scholar
• Nandi, S., Roy, H., Gummadi, A., & Saxena, A. K. (2021). Exploring spike protein as potential target of novel coronavirus and to inhibit the viability utilizing natural agents. Current Drug Targets, 22(17), 2006–2020.
   PubMed Web of Science ®Google Scholar
• Newman, L. A., Winn, R. A., & Carethers, J. M. (2021). Similarities in Risk for COVID-19 and Cancer Disparities. Clinical Cancer Research, 27, 24–27.
   PubMedGoogle Scholar
• Oren, M., & Rotter, V. (2010). Mutant p53 gain-of-function in cancer. Cold Spring Harbor Perspectives in Biology, 2(2), a001107. https://doi.org/10.1101/cshperspect.a001107
   PubMed Web of Science ®Google Scholar
• Parrinello, M., & Rahman, A. (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of Applied Physics, 52(12), 7182–7190. https://doi.org/10.1063/1.328693
   Web of Science ®Google Scholar
• Pathania, A. S., Prathipati, P., Abdul, B. A. A., Chava, S., Katta, S. S., Gupta, S. C., Gangula, P. R., Pandey, M. K., Durden, D. L., Byrareddy, S. N., & Challagundla, K. B. (2021). COVID-19 and cancer comorbidity: Therapeutic opportunities and challenges. Theranostics, 11(2), 731–753. https://doi.org/10.7150/thno.51471
   PubMed Web of Science ®Google Scholar
• Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF Chimera—A visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605–1612.
   PubMed Web of Science ®Google Scholar
• Ramaswamy, A., Nayak, L., Roy Moulik, N., Sengar, M., Chinnaswamy, G., Jobanputra, K., Shah, M. J., Kapoor, A., Joshi, A., Kumar, A., Gokarn, A., Bonda, A., Cheriyalinkal Parambil, B., Prasad, M., Bagal, B., Dhamne, C., Narula, G., Jain, H., Ghosh, J., … Prabhash, K. (2020). COVID-19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment. Cancer Medicine, 9(23), 8747–8753. https://doi.org/10.1002/cam4.3423
   PubMed Web of Science ®Google Scholar
• Richards, M., Anderson, M., Carter, P., Ebert, B. L., & Mossialos, M. (2020). The impact of the COVID-19 pandemic on cancer care. Nature Cancer, 1(6), 565–567. https://doi.org/10.1038/s43018-020-0074-y
   PubMedGoogle Scholar
• Roschewski, M., Lionakis, M. S., Sharman, J. P., Roswarski, J., Goy, A., Monticelli, M. A., Roshon, M., Wrzesinski, S. H., Desai, J. V., Zarakas, M. A., Collen, J., Rose, K. M., Hamdy, A., Izumi, R., Wright, G. W., Chung, K. K., Baselga, J., Staudt, L. M., & Wilson, W. H. (2020). Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunology, 5(48), eabd0110. https://doi.org/10.1126/sciimmunol.abd0110
   PubMed Web of Science ®Google Scholar
• Roy, H., Gummadi, A., Nayak, B. S., Nandi, S., & Saxena, A. K. (2021). Exploring the COVID-19 potential targets: Big challenges to quest specific treatment. Current Topics in Medicinal Chemistry, 21(15), 1337–1359. https://doi.org/10.2174/1568026621666210727162324
   PubMed Web of Science ®Google Scholar
• Saini, K. S., Tagliamento, M., Lambertini, M., McNally, R., Romano, M., Leone, M., Curigliano, G., & Azambuja, E d. (2020). Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. European Journal of Cancer (Oxford, England: 1990), 139, 43–50. https://doi.org/10.1016/j.ejca.2020.08.011
   PubMed Web of Science ®Google Scholar
• Shoemark, D. K., Colenso, C. k., Toelzer, C., Gupta, K., Sessions, R. B., Davidson, A. D., Berger, I., Schaffitzel, C., Spencer, J., & Mulholland, A. J. (2021). Molecular simulations suggest vitamins, retinoids and steroids as ligands of the free fatty acid pocket of the SARS-CoV-2 spike protein. Angewandte Chemie (International ed. in English), 60(13), 7098–7110.
   PubMed Web of Science ®Google Scholar
• Sinha, S. K., Shakya, A., Prasad, S. K., Singh, S., Gurav, N. S., Prasad, R. S., & Gurav, S. S. (2021). An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets. Journal of Biomolecular Structure & Dynamics, 39(9), 3244–3255.
   PubMed Web of Science ®Google Scholar
• Smith, S. M., Boppana, A., Traupman, J. A., Unson, E., Maddock, D. A., Chao, A., Dobesh, D. P., Brufsky, A., & Connor, R. I. (2021). Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID‐19. Journal of Medical Virology, 93(1), 409–415.
   PubMed Web of Science ®Google Scholar
• Spoel, D. V. D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). C. GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718. https://doi.org/10.1002/jcc.20291
   PubMed Web of Science ®Google Scholar
• Tan, C. W., Chia, W. N., Qin, X., Liu, P., Chen, M. I.-C., Tiu, C., Hu, Z., Chen, V. C.-W., Young, B. E., Sia, W. R., Tan, Y.-J., Foo, R., Yi, Y., Lye, D. C., Anderson, D. E., & Wang, L.-F. (2020). A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nature Biotechnology, 38(9), 1073–1078.
   PubMed Web of Science ®Google Scholar
• Tao, W. T., Yu, Q., Li, Y. L., Ge, M., Zhao, Y. L., & Shi, T. (2021). Exploring the interaction between Vancomycin/Teicoplanin and Receptor Binding Domain (RBD) of SARS-CoV-2. Frontiers in Chemistry, 8, 639918. https://doi.org/10.3389/fchem.2020.639918
   Google Scholar
• Tian, J., Yuan, X., Xiao, J., Zhong, Q., Yang, C., Liu, B., Cai, Y., Lu, Z., Wang, J., Wang, Y., Liu, S., Cheng, B., Wang, J., Zhang, M., Wang, L., Niu, S., Yao, Z., Deng, X., Zhou, F., … Wang, Z. (2020). Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: A multicentre, retrospective, cohort study. Lancet Oncology, 21(7), 893–903. https://doi.org/10.1016/S1470-2045(20)30309-0
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461.
   PubMed Web of Science ®Google Scholar
• Vanommeslaeghe, K., Hatcher, E., Acharya, C., Kundu, S., Zhong, S., Shim, J., Darian, E., Guvench, O., Lopes, P., Vorobyov, I., & MacKerell, A. D. Jr.(2010). CHARMM General Force Field (CGenFF): A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. Journal of Computational Chemistry, 31(4), 671–690.
   PubMed Web of Science ®Google Scholar
• Verkhivker, G. M., Agajanian, S., Oztas, D. Z., & Gupta, G. (2021). Comparative perturbation-based modelling of the SARS-CoV-2 spike protein binding with host receptor and neutralizing antibodies: structurally adaptable allosteric communication hotspots define spike sites targeted by global circulating mutations. Biochemistry, 60(19), 1459–1484. https://doi.org/10.1021/acs.biochem.1c00139
   PubMed Web of Science ®Google Scholar
• Wang, W., Donini, O., Reyes, C. M., & Kollman, P. A. (2001). Biomolecular simulations: Recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid non-covalent interactions. Annual Review of Biophysics and Biomolecular Structure, 30(1), 211–243. https://doi.org/10.1146/annurev.biophys.30.1.211
   PubMedGoogle Scholar
• Xu, P., Huang, J., Fan, Z., Huang, W., Qi, M., Lin, X., Song, W., & Yi, L. (2020). Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: A retrospective multicenter cohort study. Microbes and Infection, 22(4–5), 200–205.
   PubMed Web of Science ®Google Scholar
• Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020). Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science (New York, N.Y.), 367(6485), 1444–1448. https://doi.org/10.1126/science.abb2762
   PubMed Web of Science ®Google Scholar
• Yang, Z., Lasker, K., Schneidman-Duhovny, D., Webb, B., Huang, C. C., Pettersen, E. F., Goddard, T. D., Meng, E. C., Sali, A., & Ferrin, T. E. (2012). UCSF Chimera, MODELLER, and IMP: An integrated modeling system. Journal of Structural Biology, 179(3), 269–278.
   PubMed Web of Science ®Google Scholar
• Yao, T., Gao, Y., Cui, Q., Peng, B., Chen, Y., Li, J., Huang, C., He, C., Pu, J., Wei, J., Zhan, Y., Yan, J., Tian, J., Zhang, Z., & Liu, Z. (2020). Clinical characteristics of a group of deaths with COVID-19 pneumonia in Wuhan, China: A retrospective case series. BMC Infectious Diseases, 20(1), 695.
   PubMed Web of Science ®Google Scholar
• Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012). Allele-specific p53 mutant reactivation. Cancer Cell, 21(5), 614–625. https://doi.org/10.1016/j.ccr.2012.03.042
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Hu, S., Wang, J., Xue, Z., Wang, C., & Wang, N. (2021). Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2. Virology, 554, 83–88. https://doi.org/10.1016/j.virol.2020.12.001
   PubMed Web of Science ®Google Scholar
• Zhao, W., Zhong, Z., Xie, X., Yu, Q., & Liu, J. (2020). CT scans of patients with 2019 novel coronavirus (COVID-19) pneumonia. Theranostics, 10(10), 4606–4613. https://doi.org/10.7150/thno.45016
   PubMed Web of Science ®Google Scholar